Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of In Vivo Drug-Receptor Binding
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The in vivo muscarinic receptor binding of antimuscarinic agents (oxybutynin, solifenacin, tolterodine, and imidafenacin) used to treat urinary dysfunction in patients with overactive bladder is reviewed. Transdermal administration of oxybutynin in rats leads to significant binding of muscarinic receptors in the bladder without long-term binding in the submaxillary gland and the abolishment of salivation evoked by oral oxybutynin. Oral solifenacin shows significant and long-lasting binding to muscarinic receptors in mouse tissues expressing the M3 subtype. Oral tolterodine binds more selectively to muscarinic receptors in the bladder than in the submaxillary gland in mice. The muscarinic receptor binding of oral imidafenacin in rats is more selective and longer-lasting in the bladder than in other tissues such as the submaxillary gland, heart, colon, lung, and brain, suggesting preferential muscarinic receptor binding in the bladder. In vivo quantitative autoradiography with (+)N-[11C]methyl-3-piperidyl benzilate in rats shows significant occupancy of brain muscarinic receptors with the intravenous injection of oxybutynin, solifenacin, and tolterodine. The estimated in vivo selectivity in brain is significantly greater for solifenacin and tolterodine than for oxybutynin. Imidafenacin occupies few brain muscarinic receptors. Similar findings for oral oxybutynin were observed with positron emission tomography in conscious rhesus monkeys with a significant disturbance of short-term memory. The newer generation of antimuscarinic agents may be advantageous in terms of bladder selectivity after systemic administration.
Abstract
The in vivo muscarinic receptor binding of antimuscarinic agents (oxybutynin, solifenacin, tolterodine, and imidafenacin) used to treat urinary dysfunction in patients with overactive bladder is reviewed. Transdermal administration of oxybutynin in rats leads to significant binding of muscarinic receptors in the bladder without long-term binding in the submaxillary gland and the abolishment of salivation evoked by oral oxybutynin. Oral solifenacin shows significant and long-lasting binding to muscarinic receptors in mouse tissues expressing the M3 subtype. Oral tolterodine binds more selectively to muscarinic receptors in the bladder than in the submaxillary gland in mice. The muscarinic receptor binding of oral imidafenacin in rats is more selective and longer-lasting in the bladder than in other tissues such as the submaxillary gland, heart, colon, lung, and brain, suggesting preferential muscarinic receptor binding in the bladder. In vivo quantitative autoradiography with (+)N-[11C]methyl-3-piperidyl benzilate in rats shows significant occupancy of brain muscarinic receptors with the intravenous injection of oxybutynin, solifenacin, and tolterodine. The estimated in vivo selectivity in brain is significantly greater for solifenacin and tolterodine than for oxybutynin. Imidafenacin occupies few brain muscarinic receptors. Similar findings for oral oxybutynin were observed with positron emission tomography in conscious rhesus monkeys with a significant disturbance of short-term memory. The newer generation of antimuscarinic agents may be advantageous in terms of bladder selectivity after systemic administration.
참고문헌 (70)
- Wein AJ, "Definition and epidemiology of overactive bladder", Urology, 60(5 Suppl 1), pp.7~12 (2002)
- Anderson KE, "Pharmacology of lower urinary tract smooth muscles and penile erectile tissues", Pharmacol Rev, 45, pp.253~308 (1993)
- Andersson KE, "Antimuscarinics for treatment of overactive bladder", Lancet Neurol, 3, pp.46~53 (2004)
- Ouslander JG, "Management of overactive bladder", N Engl J Med, 350, pp.786~799 (2004)
- Pakulski C, "Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier", Med Sci Monit, 6, pp.314~318 (2000)
- Flicker C, "Hypersensitivity to scopolamine in the elderly", Psychopharmacology (Berl), 107, pp.437~441 (1992)
- Molchan SE, "Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model", Brain Res Brain Res Rev, 17, pp.215~226 (1992)
- -I-QNB: methodological considerations, "Nucl Med Biol", 2004, 583~590
- Holford NH, "Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models", Clin Pharmacokinet, 6, pp.429~453 (1981)
- Yamada S, "Integration of pharmacokinetics and pharmacodynamics in drug development: in vivo receptor occupancy by calcium antagonist and angiotensin II receptor antagonist", Curr Top Pharmacol, 4, pp.239~250 (1998)
- Dingemanse J, "Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview", Pharmacol Ther, 38, pp.1~52 (1988)
- Ohtsuka M, "New generation dihydropyridine calcium entry blockers: in search of greater selectivity for one tissue subtype", Gen Pharmacol, 20, pp.539~556 (1989)
- Yamada S, "Alpha 1-adrenoceptors in human prostate: characterization and binding characteristics of alpha 1-antagonists", Life Sci, 54, pp.1845~1854 (1994)
- Chapple CR, "Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience", Eur Urol, 29, pp.129~144 (1996)
- Leurs R, "Therapeutic potential of histamine H3 receptor agonists and antagonists", Trends Pharmacol Sci, 19, pp.177~183 (1998)
- Yamada S, "In vivo receptor binding of novel alpha1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia", Life Sci, 62, pp.1585~1589 (1998)
- eyman MG, "Lactamimides: a novel chemical class of calcium antagonists with diltiazem-like properties", Biochem Pharmacol, 38, pp.2459~2465 (1989)
- Yamada S, "Binding characteristics of naftopidil and alpha 1-adrenoceptor antagonists to prostatic alpha-adrenoceptors in benign prostatic hypertrophy", Life Sci, 50, pp.127~135 (1992)
- Nozawa Y, "Pharmacological profile of TH-142177, a novel orally active AT1-receptor antagonist", Fundam Clin Pharmacol, 11, pp.395~401 (1997)
- Feoktistov I, "Adenosine A2B receptors: a novel therapeutic target in asthma?", Trends Pharmacol Sci, 19, pp.148~153 (1998)
- Yarker YE, "A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability", Drugs Aging, 6, pp.243~262 (1995)
- Anderson RU, "Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group", J Urol, 161, pp.1809~1812 (1999), OROS Oxybutynin Study Group
- Sathyan G, "Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride", Br J Clin Pharmacol, 52, pp.409~417 (2001)
- Davila GW, "A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence", J Urol, 166, pp.140~145 (2001)
- Dmochowski RR, "Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence", Urology, 62, pp.237~242 (2003)
- Oki T, "Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion", J Pharmacol Exp Ther, 316, pp.1137~1145 (2006)
- Yamada S, "Brain nicotinic acetylcholine receptors. Biochemical characterization by neosurugatoxin", Mol Pharmacol, 28, pp.120~127 (1985)
- Douchamps J, "The pharmacokinetics of oxybutynin in man", Eur J Clin Pharmacol, 35, pp.515~520 (1988)
- Hughes KM, "Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers", Xenobiotica, 22, pp.859~869 (1992)
- Oki T, "In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin", Life Sci, 76, pp.2445~2456 (2005)
- Waldeck K, "Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland", J Urol, 157, pp.1093~1097 (1997)
- Ikeda K, "M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs", Arch Pharmacol, 366, pp.97~103 (2002)
- Ohtake A, "In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats", Eur J Pharmacol, 492, pp.243~250 (2004)
- Oki T, "Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice", Br J Pharmacol, 145, pp.219~227 (2005)
- N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice, "Brain Res Mol Brain Res", 2005, 6~11
- Ito Y, "Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice", Br J Pharmacol, 156, pp.1147~1153 (2009)
- Oki T, "Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice", Biol Pharm Bull, 29, pp.1397~1400 (2006)
- Guay DR, "Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity", Pharmacotherapy, 19, pp.267~280 (1999)
- Nilvebrant L, "Tolterodine--a new bladder-selective antimuscarinic agent", Eur J Pharmacol, 327, pp.195~207 (1997)
- Nilvebrant L, "Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine", Pharmacol Toxicol, 81, pp.169~172 (1997)
- Postlind H, "Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes", Drug Metab Dispos, 26, pp.289~293 (1998)
- Oki T, "Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice", Eur J Pharmacol, 529, pp.157~163 (2006)
- Pahlman I, "Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice", Arzneimittelforschung, 51, pp.125~133 (2001)
- Kobayashi F, "Effects of imidafenacin (KRP-197", ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland, 2007, pp.57, 92~100
- Yamada S, "Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder", J Pharmacol Exp Ther, 336, pp.365~371 (2011)
- Seki M, "Muscarinic receptor binding of imidafenacin in the human bladder mucosa and detrusor and parotid gland", LUTS, 3, pp.64~68 (2011)
- Masuda Y, "Development and validation of bioanalytical methods for imidafenacin (KRP-197", ONO-8025) and its metabolites in human urine by using liquid chromatography-tandem mass spectrometry, 2007, pp.21, 940~948
- Andersson KE, "Potential benefits of muscarinic M3 receptor selec tivity", Eur Urology Suppl, 1, pp.23~28 (2002)
- Maruyama S, "In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment", J Pharmacol Exp Ther, 325, pp.774~781 (2008)
- Suzuki M, "Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test", Eur J Pharmacol, 557, pp.154~158 (2007)
- Scheife R, "Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly", Clin Ther, 27, pp.144~153 (2005)
- Chapple CR, "Muscarinic receptor antagonists in the treatment of overactive bladder", Urology, 55(5A Suppl), pp.33~46 (2000)
- Clemett D, "olterodine: a review of its use in the treatment of overactive bladder", Drugs Aging, 18, pp.277~304 (2001)
- Watanabe T, "The present conditions and the prospects of a skin application drug", Drug Deliv Syst, 22, pp.450~457 (2007)
- Abrams P, "Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder", Expert Opin Pharmacother, 2, pp.1685~1701 (2001)
- Yokoyama O, "Urodynamic effects of intravesical oxybutynin chloride in conscious rats", J Urol, 155, pp.768~771 (1996)
- Kay GG, "Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly", Clin Ther, 27, pp.127~138 (2005)
- Flynn DD, "Pharmacological strategies to selectivity label and localize muscarinic receptor subtypes", Drug Dev Res, 40, pp.104~116 (1997)
- Kay GG, "Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients", J Am Geriatr Soc, 53, pp.2195~2201 (2005)
- Maruyama S, "Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder", J Urol, 175, pp.365~369 (2006)
- Ohtake A, "Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents", Biol Pharm Bull, 30, pp.54~58 (2007)
- Tsukada H, "Delivery of radioligands for positron emission tomography (PET) in the central nervous system", Adv Drug Deliv Rev, 37, pp.175~188 (1999)
- Yoshida A, "Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography", Life Sci, 87, pp.175~180 (2010)
- (+)3-MPB, "Neuroimage", 2011, 1~9
- Kobayashi F, "Pharmacological effects of imidafenacin (KRP-197", ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task, 2007, pp.57, 147~154
- Homma Y, "Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder", Int J Urol, 15, pp.986~991 (2008)
- Homma Y, "A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder", Int J Urol, 16, pp.499~506 (2009)
- Homma Y, "A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder", Int J Urol, 15, pp.809~815 (2008)
- Ohno T, "Absolute bioavailability of imidafenacin after oral administration to healthy subjects", Br J Clin Pharmacol, 65, pp.197~202 (2008)
- Skerjanec A, "The clinical pharmacokinetics of darifenacin", Clin Pharmacokinet, 45, pp.325~350 (2006)